Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
This study involved the administration of amonafide intravenously 300 mg/m2 daily times five days every three weeks to 16 refractory and relapsed myeloma patients. Doses were escalated to toxicity. These doses caused severe thrombocytopenia and granulocytopenia in seven patients. No responses were seen in this heavily pretreated group of patients.
Hanson
K H
KH
St. Luke's Hospital, Kansas City, MO.
Crowley
J
J
Salmon
S E
SE
Keppen
M
M
Braun
T J
TJ
Bonnet
J D
JD
D000225:Adenine; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D004351:Drug Resistance; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D007094:Imides; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000097:blood / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D053644:Naphthalimides; D063065:Organophosphonates; D012008:Recurrence; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced
D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine